 |
|
Association of Laboratory-Defined Aspirin Resistance With a Higher Risk of Recurrent Cardiovascular EventsA Systematic Review and Meta-analysis
Jaapjan D. Snoep, MSc;
Marcel M. C. Hovens, MD;
Jeroen C. J. Eikenboom, MD, PhD;
Johanna G. van der Bom, MD, PhD;
Menno V. Huisman, MD, PhD
Arch Intern Med. 2007;167(15):1593-1599.
Background The risk of recurrence of cardiovascular events among patients using aspirin (acetylsalicylic acid) for secondary prevention of such events remains high. Persistent platelet reactivity despite aspirin therapy, a laboratory-defined phenomenon called aspirin resistance (hereinafter, laboratory aspirin resistance), might explain this in part, but its actual contribution to the risk remains unclear. The objective of this study was to systematically review all available evidence on whether laboratory aspirin resistance is related to a higher risk of cardiovascular recurrent events.
Methods Using a predefined search strategy, we searched electronic databases. To be included in our analysis, articles had to report on patients who used aspirin for secondary cardiovascular prevention, had to contain a clear description of a method to establish the effects of aspirin on platelet reactivity, and had to report recurrence rates of cardiovascular events. Odds ratios of cardiovascular outcome of eligible studies were pooled in a random-effects model.
Results We included 15 full-text articles and 1 meeting abstract. Fifteen of these studies revealed an adverse association between laboratory aspirin resistance and occurrence of cardiovascular events. The pooled odds ratio of all cardiovascular outcomes was 3.8 (95% confidence interval, 2.3-6.1) for laboratory aspirin resistance.
Conclusion This systematic review and meta-analysis shows that patients biochemically identified as having laboratory aspirin resistance are more likely to also have "clinical resistance" to aspirin because they exhibit significantly higher risks of recurrent cardiovascular events compared with patients who are identified as (laboratory) aspirin sensitive.
Author Affiliations: Departments of General Internal Medicine and Endocrinology (Mr Snoep and Drs Hovens and Huisman), Hematology (Dr Eikenboom), and Clinical Epidemiology (Mr Snoep and Dr van der Bom), Leiden University Medical Center, Leiden, the Netherlands.
RELATED LETTERS
Laboratory-Defined Aspirin Resistance and Recurrent Cardiovascular Events
Pierre Fontana and Jean-Luc Reny
Arch Intern Med. 2008;168(5):549-550.
EXTRACT
| FULL TEXT
Is Aspirin Resistance Due to Noncompliance?
James E. Dalen
Arch Intern Med. 2008;168(5):550.
EXTRACT
| FULL TEXT
Is Aspirin Resistance Due to Noncompliance?—Reply
Jaapjan D. Snoep, Marcel M. C. Hovens, Jeroen C. J. Eikenboom, Johanna G. van der Bom, and Menno V. Huisman
Arch Intern Med. 2008;168(5):550.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Should we monitor platelet function during antiplatelet therapy?
Hjemdahl
Heart 2008;94:685-687.
FULL TEXT
The implications of aspirin resistance in renal failure
Thachil
NDT Plus 2008;1:192-193.
FULL TEXT
Laboratory-Defined Aspirin Resistance and Recurrent Cardiovascular Events
Fontana and Reny
Arch Intern Med 2008;168:549-550.
FULL TEXT
Is Aspirin Resistance Due to Noncompliance?
Dalen
Arch Intern Med 2008;168:550-550.
FULL TEXT
Is Aspirin Resistance Due to Noncompliance?--Reply
Snoep et al.
Arch Intern Med 2008;168:550-550.
FULL TEXT
Aspirin Resistance: Biological and Clinical Implications
Tseeng and Arora
J CARDIOVASC PHARMACOL THER 2008;13:5-12.
ABSTRACT
Aspirin resistance in cardiovascular disease
Biondi-Zoccai and Lotrionte
BMJ 2008;336:166-167.
FULL TEXT
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis
Krasopoulos et al.
BMJ 2008;336:195-198.
ABSTRACT
| FULL TEXT
Testing antiplatelet therapy
Gachet and Aleil
Eur Heart J Suppl 2008;10:A28-A34.
ABSTRACT
| FULL TEXT
|
